The BioPharma Site Solutions Summit is an esteemed conference reserved for invited attendees, bringing together influential clinical trial’s decision makers, research site leaders and innovative suppliers and solution providers. Our [….]
The Festival of Genomics & Biodata in Boston 2024
Published on :The Festival of Genomics and Biodata is returning to Boston! Join us on Wednesday, June 12th – Thursday, June 13th, 2024, at the Boston Convention & Exhibition Center for inspirational [….]
Discovery US 2023
Published on :Join and network with over 250 industry leaders at Discovery US 2023, where we will address the latest advancements in target identification, validation and HIT optimisation. The 2-day programme addresses [….]
Biomarkers US 2023
Published on :Gain a US perspective on the latest technologies and novel biomarkers driving forward translational research and precision medicine
Gain Therapeutics Announces Issuance of Two New PCT Patents Covering GBA and GALC Modulator Compounds for Treatment of CNS Disorders
Published on :Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”), a biotechnology company focused on redefining drug discovery by identifying and optimizing allosteric binding sites that have never before been targeted, today announced the publication of two PCT patents. PCT/IB2020/061158 and PCT/IB2020/0611156 are directed at compounds targeting misfolded beta-glucocerebrosidase (GBA) and galactosylceramidase (GALC) respectively, addressing central nervous system (CNS) and demyelinating disorders such as Parkinson’s Disease, Lewy body dementia and Alzheimer’s.
Bethesda’s Gain Therapeutics Announces Pricing of IPO of Common Stock
Published on :Gain Therapeutics Announces Pricing of Initial Public Offering of Common Stock BETHESDA, Md., March 18, 2021 (GLOBE NEWSWIRE) — Gain Therapeutics, Inc. (“Gain”) today announced the pricing of its initial [….]
5 Questions with Destinie Burgan, Upstream Supervisor of Manufacturing, Emergent BioSolutions
Published on :“5 Questions With…” is a weekly BioBuzz series where we reach out to interesting people in the BioHealth Capital Region to share a little about themselves, their work, and maybe something completely unrelated. March is WOMEN’S HISTORY MONTH and BioBuzz will celebrate by featuring Women in the BioHealth industry all month, especially in “5 Questions With…”. This week we continue the series with Destinie Burgan, Upstream Supervisor of Manufacturing, Emergent BioSolutions.
5 Questions with Doug White, Senior Vice President, Devices Business Unit Head, Emergent BioSolutions
Published on :Doug White joined Emergent in 2017 and serves as head of the devices business unit. He previously served as vice president and general manager of Molecular Diagnostics & Women’s Health at Becton Dickenson Diagnostics. Before joining Becton Dickenson Diagnostics, he was chief executive officer of OpGen Inc.